financetom
Business
financetom
/
Business
/
Aeluma Insider Sold Shares Worth $2,335,089, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Aeluma Insider Sold Shares Worth $2,335,089, According to a Recent SEC Filing
Oct 7, 2025 12:38 AM

03:27 AM EDT, 10/07/2025 (MT Newswires) -- Mark N. Tompkins, 10% Owner, on October 02, 2025, sold 129,751 shares in Aeluma ( ALMU ) for $2,335,089. Following the Form 4 filing with the SEC, Tompkins has control over a total of 2,676,582 common shares of the company, with 2,676,582 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1828805/000121390025096784/xslF345X05/ownership.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
McCoy Global to Launch Automatic Share Purchase Program
McCoy Global to Launch Automatic Share Purchase Program
Mar 24, 2025
09:16 AM EDT, 03/24/2025 (MT Newswires) -- McCoy Global ( MCCRF ) , which rose 3.1% last Friday, on Monday said it established an automatic share purchase plan (ASPP) with its broker to facilitate buybacks of common shares under its previously announced Normal Course Issuer Bid (NCIB) of up to 1.6 million common shares. Our share repurchase program is an...
Tenaya Therapeutics Says Gene Therapy Candidate Improves Heart Function in Preclinical Trial
Tenaya Therapeutics Says Gene Therapy Candidate Improves Heart Function in Preclinical Trial
Mar 24, 2025
09:22 AM EDT, 03/24/2025 (MT Newswires) -- Tenaya Therapeutics ( TNYA ) said Monday that preclinical data for TN-201, its gene therapy candidate for myosin-binding protein C3-associated hypertrophic cardiomyopathy, showed improved heart function. Published preclinical data also showed extended survival and lower cardiac biomarkers associated with fibrosis and heart failure, the company said. A mouse surrogate of TN-201 was tested...
Why Tonix Pharmaceuticals (TNXP) Stock Is Rising
Why Tonix Pharmaceuticals (TNXP) Stock Is Rising
Mar 24, 2025
Tonix Pharmaceuticals Holding Corp ( TNXP ) shares are trading higher by 25.3% to $28.85 during Monday’s session after the company announced that the FDA will not require an Advisory Committee meeting for its New Drug Application for TNX-102 SL, a potential new treatment for fibromyalgia. What To Know: CEO Seth Lederman expressed confidence in the drug's potential to introduce...
Itron Brings to Market Product for Grid Control Challenges
Itron Brings to Market Product for Grid Control Challenges
Mar 24, 2025
09:20 AM EDT, 03/24/2025 (MT Newswires) -- Itron ( ITRI ) said Monday it is making available a non-wire product that addresses utility grid visibility and control challenges, in collaboration with Schneider Electric and Microsoft ( MSFT ) . The company said its Grid Edge Intelligence will be integrated with Schneider Electric's Digital Grid products and Microsoft's ( MSFT )...
Copyright 2023-2026 - www.financetom.com All Rights Reserved